The FDA has submitted a proposed CBD enforcement policy to the White House for review, signaling a possible shift in U.S. regulations for hemp-derived cannabis products.
The U.S. Food and Drug Administration (FDA) submitted a proposed policy on cannabis product enforcement to the White House for review, signaling a possible shift in how cannabidiol (CBD) products are regulated in the United States. The proposal, titled “Cannabidiol Products Compliance and Enforcement Policy,” is currently under review by the Office of Information and Regulatory Affairs (OIRA), part of the White House Office of Management and Budget.
The proposal's submission coincides with growing pressure on federal agencies to clarify regulations pertaining to hemp-derived products, even if the proposal's content has not yet been made public. A congressional deadline for the FDA to release lists of naturally occurring cannabinoids in cannabis, including THC-class chemicals and other cannabinoids with comparable effects was missed earlier this year.
President Donald Trump signed funding legislation that includes the regulation, which also calls for more precise specifications of THC serving sizes and hemp product packaging. Simultaneously, the measure reinstates limits on a number of hemp products that were made legal by the 2018 Farm Bill. The new restrictions are anticipated to go into effect in November.
Industry observers are also linking the FDA proposal to a broader federal initiative involving CBD access through healthcare programs. The Centers for Medicare & Medicaid Services (CMS) is reportedly developing a pilot program that could allow certain patients, including eligible Medicare beneficiaries, to receive coverage for hemp-derived CBD products. The initiative is tied to a wider policy shift following an executive order to move marijuana from Schedule I to Schedule III under federal law.
However, officials have not confirmed whether the FDA’s proposal is connected to the cannabinoid classification requirement, healthcare coverage changes, or a separate regulatory effort aimed at establishing clearer federal rules for CBD products.
